TY - JOUR
T1 - Atopic dermatitis
T2 - Skin care and topical therapies
AU - Fleischer, David M.
AU - Udkoff, Jeremy
AU - Borok, Jenna
AU - Friedman, Adam
AU - Nicol, Noreen
AU - Bienstock, Jeffrey
AU - Lio, Peter A
AU - Tollefson, Megha
AU - Eichenfield, Lawrence F.
N1 - Publisher Copyright:
© 2017 Frontline Medical Communications.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy.
AB - Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy.
UR - http://www.scopus.com/inward/record.url?scp=85051826744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051826744&partnerID=8YFLogxK
U2 - 10.12788/j.sder.2017.035
DO - 10.12788/j.sder.2017.035
M3 - Article
C2 - 28895956
AN - SCOPUS:85051826744
SN - 1085-5629
VL - 36
SP - 104
EP - 111
JO - Seminars in cutaneous medicine and surgery
JF - Seminars in cutaneous medicine and surgery
IS - 3
ER -